Newsroom

People

Filter by year

#total results found

September 29, 2025
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Conexxence® and Bomyntra® (denosumab-bnht)

This designation helps broaden access to these high-quality biological medicines which support quality patient care while reducing costs.
September 25, 2025
Fresenius Kabi Receives Two Major Awards for Supply and Service Excellence from Vizient®

The Supplier of the Year Awards recognize outstanding suppliers by category that support Vizient’s mission to strengthen providers’ delivery of better, more affordable care.
People | September 7, 2025
Fresenius Kabi and AABB Announce 20th Anniversary of Blood Collectors Week, September 7–14, 2025, Honoring Lifesaving Blood Collection Professionals

This year marks a significant milestone – two decades of recognizing the professionals who make the gift of blood donation possible and support patients across the country every day.
August 26, 2025
Fresenius leads new EASYGEN consortium aimed at decentralizing CAR-T cell therapy and improving hospital workflows

The global healthcare company Fresenius is collaborating with other companies and academic institutions with the goals of accelerating the manufacturing of CAR-T cell therapy, making it more cost-effective, and improving patient access across Europe.
July 17, 2025
Fresenius Kabi Receives 2025 Premier Supplier Legacy Award

Fresenius Kabi received the 2025 Supplier Legacy Award from Premier, Inc., a leading technology-driven healthcare performance improvement company.
July 1, 2025
Fresenius Expands Biosimilars Portfolio With The Launch of Denosumab Biosimilars in the U.S.

Fresenius Kabi, has introduced two new biosimilars - Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) - in the United States.
May 20, 2025
Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg per 30 mL Multi-Dose Vials

Epinephrine Injection, USP, is available through Fresenius Kabi in the United States in 30 mg per 30 mL multi-dose vials.
May 19, 2025
FDA Grants Interchangeable Designation to Fresenius Kabi’s biosimilar Otulfi® (ustekinumab-aauz)

The U.S Food and Drug Administration (FDA) designated Fresenius Kabi’s Otulfi® (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara® (ustekinumab)
April 28, 2025
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Otulfi® (ustekinumab-aauz)

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® (ustekinumab-aauz).
March 27, 2025
Fresenius Receives FDA Approval for Their Denosumab Biosimilars and Secures Global Settlement Agreement

Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence®** (denosumab-bnht) and Bomyntra®** (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the U.S. Food and Drug Administration (FDA).
March 3, 2025
Fresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)

Fresenius Kabi announces ustekinumab biosimilar Otulfi® (ustekinumab-aauz) developed by Formycon AG, is now available in the United States
February 13, 2025
Angels for Change Launches Project GOLD

Angels for Change (A4C) announces the pilot launch of Project GOLD (Generic Oncology Lifesaving Drugs), a new resiliency program that establishes an onshore buffer supply of six essential medications that are used to treat cancer.
February 10, 2025
Fresenius Kabi Introduces Calcitonin Salmon Injection, USP Synthetic

Fresenius Kabi, an operating company of Fresenius, announced today it has introduced Calcitonin Salmon Injection, USP Synthetic, a calcium regulator, for the treatment of symptomatic Paget’s disease of the bone and hypercalcemia.
February 4, 2025
Angels for Change Announce 2024 Change Maker of the Year Award.

Presented to individuals who have made significant strides in advocating for and securing access to essential medicines for patients, driving meaningful change in the race to end drug shortages.
January 28, 2025
Fresenius Kabi Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency with the Aurora Xi Plasmapheresis System

Fresenius Kabi, an operating company of Fresenius, specializing in lifesaving medicines and technologies, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Adaptive Nomogram - an alternate algorithm that will be available in the Aurora Xi Plasmapheresis System - designed to optimize plasma collection efficiency.
December 17, 2024
Fresenius Kabi Launches Epinephrine Injection, USP Expanding U.S. Pharma Portfolio

Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers.
December 10, 2024
Ori Biotech and Fresenius Kabi Collaborate to Advance Modular, Scalable Manufacturing of Cell and Gene Therapies

Ori Biotech Ltd., a leader in cell and gene therapy manufacturing technology, and Fresenius Kabi, an operating company of Fresenius, today announced a collaboration to integrate the IRO® platform with Fresenius Kabi’s upstream and downstream processing technologies.
November 21, 2024
Fresenius Kabi Submits 510(k) Notification for the Aurora Xi Plasmapheresis System Software Version 2.0 with New Nomogram

Fresenius Kabi, an operating company of Fresenius, announced today that it has submitted a 510(k) notification to the U.S. Food and Drug Administration seeking clearance of the Aurora Xi Plasmapheresis System software version 2.0.
November 14, 2024
Fresenius Kabi Receives 2024 Novaplus Program Excellence Award from Vizient

Fresenius Kabi, an operating company of Fresenius, received a Novaplus Program Excellence Award from Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company. The recognition was announced at the Vizient Connections Summit in Las Vegas.
October 29, 2024
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code and Pass-Through Payment Status for Tyenne® (tocilizumab-aazg)

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code and granted pass-through payment status for Tyenne® (tocilizumab-aazg).
October 17, 2024
Fresenius Kabi Inducts 12 into National Blood Donation Hall of Fame

Fresenius Kabi, an operating company of Fresenius, today named 12 new inductees into the National Blood Donation Hall of Fame. Nominated by blood centers across the U.S., the honorees were chosen for their extraordinary commitment to donating blood or for encouraging blood donation.
October 16, 2024
Cellular Origins, Fresenius Kabi Sign Development Agreement for Scalable Automation of Cell and Gene Therapy Manufacturing

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announces today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs).
September 30, 2024
Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi(TM)* (ustekinumab-aauz)

Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved OtulfiTM (ustekinumab-aauz), its ustekinumab biosimilar referencing Stelara® ** (ustekinumab). OtulfiTM is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. Fresenius Kabi is further continuing its momentum, striving at expanding its strong Biopharma platform, which is a substantial cornerstone of #FutureFresenius.
September 1, 2024
Fresenius Kabi and AABB Announce Start of 19th Annual Blood Collectors Week

Fresenius Kabi and AABB Announce Start of 19th Annual Blood Collectors Week, September 1-7, 2024. Honoring blood collection professionals and their life-saving impact on patient care
August 27, 2024
Fresenius Kabi Expands Women’s Health Portfolio with New Generic Option for Reproductive Health

Fresenius Kabi announced today it has launched Cetrorelix Acetate for Injection kit, an FDA-approved, cost-effective, generic option for women’s reproductive health. Cetrorelix Acetate for Injection is available immediately from Fresenius Kabi in a kit that contains one single-dose vial (0.25 mg cetrorelix), one pre-filled syringe with 1 mL sterile water for injection, one 20-gauge needle, and one 27-gauge needle.
August 5, 2024
Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. for Supply Chain Innovation

Fresenius Kabi, an operating company of Fresenius, has received the 2024 Trailblazer Award from Premier Inc., a leading technology-driven health care improvement company. Premier members comprise approximately 4,350 U.S. hospitals, health systems and more than 300,000 other providers and organizations in health care.
July 10, 2024
Arunesh Verma Joins Fresenius Kabi USA as President

Fresenius Kabi announced today that Arunesh Verma has joined the company as president of Fresenius Kabi USA and a member of the company’s global Executive Leadership Team, reporting to Pierluigi Antonelli, CEO of Fresenius Kabi.
July 2, 2024
Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States

Fresenius, via its operating company Fresenius Kabi, announced today the immediate availability in the U.S. of its biosimilar Tyenne® (tocilizumab-aazg), in a subcutaneous formulation, which will increase access to affordable and cost-effective treatment options for use in the treatment in chronic autoimmune diseases.
May 29, 2024
Angels for Change 2024 Drug Shortage Guardian Awarded to Fresenius Kabi USA

Angels for Change, a global non-profit on a mission to end drug shortages, presented the organization’s 2024 Drug Shortage Guardian Award to Fresenius Kabi USA, a health care company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition.
April 15, 2024
Fresenius Accelerates Momentum in its (Bio) Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.

Fresenius, via its operating company Fresenius Kabi, announced today the immediate U.S. availability of Tyenne® (tocilizumab-aazg), a biosimilar of Actemra® (tocilizumab). Tyenne®, for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation.
March 7, 2024
Fresenius Kabi’s Biosimilar Tyenne® (tocilizumab-aazg) becomes the first IV and Subcutaneous tocilizumab biosimilar approved by the FDA

Fresenius Kabi, a global health care company that specializes in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Tyenne®* (tocilizumab-aazg), its tocilizumab biosimilar referencing Actemra®** (tocilizumab). Tyenne® becomes the first tocilizumab biosimilar with both IV and subcutaneous formulations approved by the FDA. In accordance with its patent settlement agreement with Genentech, Fresenius Kabi has a license to market its tocilizumab products in the U.S. commencing on the license dates, which are confidential.
February 28, 2024
Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP

Fresenius Kabi announced today it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms of cancer. Now available in the U.S., Cyclophosphamide for Injection, USP is the newest addition to Fresenius Kabi’s broad portfolio of generic oncology injectables that help make cancer therapies more affordable and accessible.
January 29, 2024
Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections

Fresenius Kabi announced today it has introduced Posaconazole Injection, a generic substitute for Noxafil®, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system. Now available in the U.S., Posaconazole Injection is the newest addition to Fresenius Kabi’s portfolio of more than 30 anti-infective molecules.
December 14, 2023
Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix® Infusion System

Fresenius Kabi announced today it has signed a multiyear agreement under which the Mayo Clinic is expected to purchase 10,000 Ivenix® large-volume infusion pumps for its hospitals and clinics in Minnesota, Arizona and Florida.
October 10, 2023
Fresenius Kabi Celebrates 25th Anniversary of National Blood Donation Hall of Fame by Honoring 2023 Heroes

Fresenius Kabi marked the 25th anniversary of its partnership with blood donation centers by naming the 12 newest inductees into the Fresenius Kabi National Blood Donation Hall of Fame. The latest honorees were nominated by blood centers across the United States for their exemplary commitment to donating blood and/or encouraging blood donation.
October 9, 2023
Fresenius Kabi Introduces Smart Labels for Diprivan® with Embedded Fully Interoperable +RFID Technology

Fresenius Kabi announced today it has introduced +RFID smart labels for Diprivan® (Propofol) Injectable Emulsion, USP, 200 mg per 20 mL in single-dose vials, sold in the United States. The +RFID labels are now fully compatible with all major RFID kit and tray systems in the U.S.
October 3, 2023
Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient

Fresenius Kabi has been named the 2023 Supplier Partner of the Year by Vizient, Inc., the nation’s largest provider-driven health care performance improvement company. The recognition was celebrated September 18-21 at the 2023 Vizient Connections Summit in Las Vegas.
October 2, 2023
Fresenius Kabi Selected for Second Consecutive Year to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange

Fresenius Kabi has been selected to exhibit its Ivenix Infusion System at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange on Oct. 3 in Grapevine, Texas.
September 14, 2023
Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi

Fresenius Kabi announced today it has signed an agreement with Virginia Oncology Associates (VOA) under which VOA will purchase the Ivenix Infusion System to deliver medications for its patients. VOA specializes in treating people with cancer and blood disorders by providing access to innovative therapies and technologies.
September 3, 2023
Fresenius Kabi and AABB Announce Start of 18th Annual Blood Collectors Week September 3-9, 2023

Fresenius Kabi and AABB proudly announce the dates of the 18th annual Blood Collectors Week, which runs September 3-9, 2023. Throughout the week, dedicated individuals who make blood collection possible, including phlebotomists, apheresis operators, medical directors, donor recruiters, technicians, and drivers, are honored for their vital role as the connection between blood donors and patients relying on blood for medical conditions.
August 24, 2023
Fresenius Kabi and Lupagen Enter into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside

Fresenius Kabi and Lupagen Inc. announced today the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside.
August 9, 2023
Fresenius Kabi Launches Plerixafor Injection

Fresenius Kabi announced today it has introduced Plerixafor Injection, a generic equivalent to Mozobil®, available immediately in the United States in a 24 mg per 1.2 mL single dose vial.
August 8, 2023
Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection

Fresenius Kabi announced today it has launched Gadobutrol Injection, a generic substitute for the contrast agent Gadavist®, which is used in magnetic resonance imaging (MRI) procedures.
July 21, 2023
Supporting the Drug Supply Following the Recent Tornado in North Carolina

In the wake of the tornado damage to a Pfizer injectables plant in North Carolina on Wednesday July 19, 2023, Fresenius Kabi activated its emergency response team and is in contact with the U.S. Food and Drug Administration’s Drug Shortage Staff (DSS) to help prevent and mitigate potential disruptions to the supply chain of essential medicines. We have also offered assistance to Pfizer, and we wish them and their employees a smooth and safe recovery of their operations.
July 11, 2023
Fresenius Kabi Introduces New Presentation for Fentanyl Citrate Injection, USP in Simplist® Ready-to-Administer Prefilled Syringes

Fresenius Kabi announced today the launch and immediate availability in the U.S. of Fentanyl Citrate Injection, USP in 100 mcg per 2 mL Simplist® ready-to-administer prefilled syringes, the only 100 mcg per 2 mL presentation available on the market in a manufacturer-prepared prefilled syringe.
July 10, 2023
Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment

Fresenius Kabi announced today it has launched Ganirelix Acetate Injection, a generic fertility drug, as part of the company’s expansion in women’s health. Ganirelix Acetate Injection is available immediately from Fresenius Kabi in 250 mcg/0.5 mL prefilled syringes.
July 3, 2023
IDACIO® (adalimumab-aacf) Now Available in the United States

Fresenius Kabi announced today the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira® (adalimumab). IDACIO is available in a self-administered prefilled syringe and a self-administered pre-filled pen (autoinjector).
June 29, 2023
Metrodora Institute, a Leader in Treating Complex Conditions, Chooses the Ivenix Infusion System from Fresenius Kabi

Fresenius Kabi announced today that its Ivenix® Infusion System has been selected by the Metrodora Institute to meet the Institute’s infusion medicine needs. The Metrodora Institute is an integrated, multidisciplinary medical and research center dedicated to treating neuroimmune axis disorders.
June 21, 2023
Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection

Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the diagnostic pharmaceutical agent, Sincalide for Injection, an authorized generic for Bracco Diagnostics Inc.’s Kinevac® (Sincalide for Injection) product. The new product broadens Fresenius Kabi’s radiology portfolio and is available immediately in the United States.
June 14, 2023
Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio

Fresenius Kabi announced today the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict®. Fresenius Kabi Vasopressin Injection, USP is an approved treatment option for adults with vasodilatory shock and is available in a 20 Units per 1 mL Single Dose Vial.
May 31, 2023
Supporting Patient Safety: Fresenius Kabi Expands Ready-to-Administer Portfolio with Diazepam Injection, USP in Simplist® Prefilled Syringe

Fresenius Kabi announced today the launch and immediate availability in the U.S. of Diazepam Injection, USP in 10 mg per 2 mL Simplist® ready-to-administer prefilled syringes.
May 30, 2023
Fresenius Kabi Launches RFID-Enabled Rocuronium Bromide Injection, its First Product Compatible with Bluesight's KitCheck System

Fresenius Kabi, a leading provider of injectable medications, announced today it has launched Rocuronium Bromide Injection with advanced RFID-enabled labels in the United States. Rocuronium Bromide Injection is part of Fresenius Kabi's +RFID™ portfolio of smart-labeled medications, designed to help enhance patient safety and support a more-efficient medication inventory process. This will mark the first +RFID product that is compatible with Bluesight’s KitCheck product, the leading kit and tray solution for American hospitals allowing +RFID products to be used across all major RFID kit and tray vendors.
May 23, 2023
Fresenius Kabi Awarded Breakthrough Technology Agreement with Premier, Inc. for the Ivenix Infusion System

Fresenius Kabi announced today it has been awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. Effective May 1, 2023, the new agreement allows Premier members, at their discretion, to benefit from special pricing and terms pre-negotiated by Premier for the Ivenix Infusion System from Fresenius Kabi.
May 16, 2023
CMS grants Fresenius Kabi permanent, product-specific Q-Code for Stimufend® (pegfilgrastim-fpgk)

Fresenius Kabi announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent product-specific Q-code for Stimufend® (pegfilgrastim-fpgk). Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code assigned to Stimufend is effective for patients administered Stimufend on and after April 1, 2023. The KABICARE™ patient services hub is available to facilitate successful access and reimbursement.
April 17, 2023
Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix Infusion System

Fresenius Kabi announced today its Ivenix Infusion System has received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company. Vizient members include more than half of all acute care hospitals in the United States, including 97 percent of U.S. academic medical centers.
February 16, 2023
Stimufend® (pegfilgrastim-fpgk) Now Available in the United States

Fresenius Kabi announced today the immediate availability in the U.S. of Stimufend® (pegfilgrastim-fpgk), the company’s biosimilar to Neulasta® (pegfilgrastim), for use in patients at risk for febrile neutropenia, a common side effect of many anti-cancer medications. Stimufend is available in a single-dose, pre-filled syringe that delivers 6mg/0.6mL solution for subcutaneous injection.
January 10, 2023
Fresenius Kabi’s Ivenix Infusion System Goes Live at San Luis Valley Health

Fresenius Kabi announced today that its Ivenix Infusion System has been successfully implemented at San Luis Valley Health in Colorado.
December 15, 2022
Fresenius Kabi Targets Treatment of Certain Seizures with Launch of Generic Lacosamide Injection, USP

Fresenius Kabi announced today the immediate availability in the U.S. of Lacosamide Injection, USP, a generic equivalent to VIMPAT®. Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in 200 mg per 20 mL single-dose vials.
December 14, 2022
Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio® (adalimumab-aacf)

Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved its citrate-free adalimumab biosimilar Idacio®* for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira®** (adalimumab).
December 8, 2022
Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Fresenius Kabi announced today it has introduced Pralatrexate Injection, a generic equivalent to Folotyn®, for the treatment of relapsed or refractory peripheral T-cell lymphoma. Fresenius Kabi Pralatrexate Injection is available immediately in the United States and is the newest addition to the company’s injectable oncology medicine portfolio, the largest in U.S. health care.
December 5, 2022
Fresenius Kabi Introduces KabiCare Nutrition Resources for U.S. Parenteral Nutrition Products

Fresenius Kabi announced today it has introduced KabiCare Nutrition Resources in the United States as part of its KabiCare patient support program. The KabiCare Nutrition Resources program provides support for insurance reimbursement questions including a helpline staffed by experts to provide billing and coding support, insurance support such as benefit investigation, prior authorization and claims appeals.
November 9, 2022
Fresenius Kabi Announces 2022 Inductees to Blood Donation Hall of Fame

Fresenius Kabi today announced the 12 newest inductees into the Fresenius Kabi Blood Donation Hall of Fame. For 24 years, the Hall of Fame has recognized and shared the unique stories of those who are passionate about and committed to blood donation.
October 11, 2022
Fort HealthCare Goes Live with Smart Pump Interoperability with the Ivenix Infusion System from Fresenius Kabi

Fresenius Kabi announced today the successful smart pump interoperability of its Ivenix Infusion System at Fort HealthCare, a regional health care provider in Wisconsin.
October 6, 2022
Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient

Fresenius Kabi has been named the 2022 Pharmaceutical Supplier Partner of the Year by Vizient, Inc., the nation’s largest member-driven health care performance improvement company. The recognition was September 19-21 at the 2022 Vizient Connections Summit in Las Vegas.
October 3, 2022
Fresenius Kabi Expands Contrast Agent Portfolio with Launch of Gadoterate Meglumine Injection, USP

resenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem®. This is the second contrast agent introduced by Fresenius Kabi in the United States this year. Fresenius Kabi introduced Iodixanol Injection, USP in July during a nationwide shortage.
September 13, 2022
Fresenius Kabi Selected to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange

Fresenius Kabi has been selected to exhibit the Ivenix Infusion System at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17, 2022, in Dallas.
September 6, 2022
Stimufend® (pegfilgrastim-fpgk) a Fresenius Kabi biosimilar receives FDA approval

Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved its biosimilar, Stimufend® (pegfilgrastim-fpgk), for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. The company expects to launch the product in a prefilled syringe early next year and in an on-body injector following FDA approval.
September 4, 2022
Fresenius Kabi and AABB Celebrate 17th Annual Blood Collectors Week from September 4-10, 2022

Fresenius Kabi and AABB announced today the official start of the 17th annual Blood Collectors Week celebration, which runs September 4-10, 2022.
August 8, 2022
Fresenius Kabi, a Leader in Injectable Medicines, Introduces Data Matrix Barcodes on all Drugs as part of Companywide Commitment to Medication Safety

Fresenius Kabi announced today the introduction of a three-year plan to add GS1 Data Matrix barcodes to its pharmaceutical portfolio of vials, syringes, IV solutions and parenteral nutrition products at the unit of use.
August 1, 2022
Fresenius Kabi’s Biologic License Application for Biosimilar Candidate Tocilizumab Accepted for Review in the U.S.

Fresenius Kabi, a global healthcare company that specializes in pharmaceuticals, medical technologies and clinical nutrition products for critical and chronic conditions, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s 351(k) Biologics License Application (BLA) for MSB11456, the company’s biosimilar candidate for Actemra®*(tocilizumab).
July 29, 2022
Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa

Fresenius Kabi announced today it has introduced Thiotepa for Injection, USP, in the United States. Thiotepa, a generic equivalent to Tepadina®, is the newest addition to the company’s injectable oncology portfolio – the most comprehensive in the industry.
July 25, 2022
Fresenius Kabi Expands Ready-to-Administer Portfolio with Glycopyrrolate Injection, USP Simplist® Prefilled Syringe

Fresenius Kabi announced today the immediate availability in the U.S. of Glycopyrrolate Injection, USP in 0.6 mg per 3 mL Simplist® ready-to-administer prefilled syringes.
July 18, 2022
Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of Iodixanol Injection, USP, a product the U.S. Food and Drug Administration (FDA) lists as being in shortage nationwide.
July 12, 2022
Romidepsin for Injection Available from Fresenius Kabi

Fresenius Kabi announced today the immediate availability in the United States of Romidepsin for Injection, the newest addition to the company’s broad portfolio of injectable oncology medicines.
June 14, 2022
Fresenius Kabi Expands RFID Compatibility to Improve Hospital Inventory Management

Fresenius Kabi announced today that its growing +RFID™ portfolio of radio frequency tagged medications is now compatible with AmerisourceBergen’s medication tray solution. AmerisourceBergen is a global health care company and one of the largest pharmaceutical distributors in the United States.
May 31, 2022
Fresenius Kabi Introduces PEMEtrexed for Injection, USP in the U.S.

Fresenius Kabi announced today the immediate availability in the U.S. of PEMEtrexed for Injection, USP, a new generic equivalent to Alimta®. Fresenius Kabi produces its PEMEtrexed for Injection, USP in the United States, where the company offers the most comprehensive injectable oncology portfolio of any pharmaceutical manufacturer.
May 18, 2022
Dr. Brandee Pappalardo Joins Fresenius Kabi as Chief Medical Officer for North America

Fresenius Kabi announced today that Brandee Pappalardo, Ph.D., M.P.H. has joined the company as senior vice president and Chief Medical Officer for North America. Dr. Pappalardo reports to John Ducker, president and CEO of Fresenius Kabi in North America and is a member of the company’s North America executive committee.
May 4, 2022
Fresenius Kabi Completes Acquisition of Ivenix

Following the announced closing of the acquisition of Ivenix and its advanced infusion pump technology, Fresenius Kabi now offers health care professionals in the United States a broad and expanding portfolio of advanced infusion pumps and solutions to meet needs across the continuum of care.
May 2, 2022
Fresenius Kabi Introduces New Generic for the Treatment of Multiple Myeloma

Fresenius Kabi announced today it has introduced Bortezomib for Injection, a new generic equivalent to Velcade® in the U.S. and the newest addition to the most comprehensive injectable oncology portfolio in the industry.
April 27, 2022
Fresenius Kabi Introduces Calcium Gluconate in Sodium Chloride Injection in Ready-to-Administer freeflex® Bags

Fresenius Kabi announced today it has introduced two new presentations of Calcium Gluconate in Sodium Chloride Injection in the United States in the company’s proprietary, ready-to-administer freeflex® containers.
April 13, 2022
Fresenius Kabi Introduces Copay Assistance for Cancer Treatments Using Generic Medicines

Fresenius Kabi announced today it has introduced KabiConnect, part of the KabiCare patient support program in the United States, to offer copay assistance for the company’s generic oncology medicines. Fresenius Kabi offers the most comprehensive portfolio of generic injectable oncology medicines in the U.S.
March 31, 2022
Next generation patient care: Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix

First steps in executing Fresenius Kabi’s “Vision 2026” growth strategy
March 24, 2022
Fresenius Kabi Announces FDA Approval of SMOFlipid® Lipid Injectable Emulsion for Pediatric Patients Requiring Parenteral Nutrition

resenius Kabi announced today it has been granted an expanded indication for SMOFlipid® Lipid Injectable Emulsion (ILE) for pediatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age.
March 14, 2022
Fresenius Kabi Receives U.S. Food and Drug Administration 510(k) Clearance for Wireless Agilia® Connect Infusion System with Vigilant® Software Suite-Vigilant® Master Med Technology

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for its wireless Agilia® Connect Infusion System which includes the Agilia® Volumetric Pump and the Agilia® Syringe Pump with Vigilant® Software Suite-Vigilant® Master Med technology. The Agilia Connect volumetric pump and syringe pump are the first to be cleared by following TIR101 standards, which were developed by the Association for the Advancement of Medical Instrumentation (AAMI) in 2021.
March 7, 2022
Fresenius Kabi Issues Voluntary Recall of Sodium Acetate Injection, USP Due to the Presence of Particulate Matter

Fresenius Kabi USA is voluntarily recalling seven lots of Sodium Acetate Injection, USP, 400 mEq/100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial to the user level due to the presence of particulate matter found in reserve and/or stability sample vials.
November 10, 2021
Omnicell and Fresenius Kabi Collaborate to Enhance Management of Controlled Substances in U.S. Hospitals

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, and Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition, are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas.
November 9, 2021
Fresenius Kabi Announces 2021 Inductees to Blood Donation Hall of Fame

Fresenius Kabi announced today it inducted 12 people and groups as the 2021 class of the Fresenius Kabi Blood Donation Hall of Fame. The nationwide program recognizes and shares the unique stories of people who are passionate about and committed to blood donation.
October 14, 2021
Fresenius Kabi USA and Phlow Corp. Announce Alliance to Enhance the Supply of Essential Medicines for U.S. Patients

Fresenius Kabi USA, a healthcare company that specializes in life-saving medicines and technologies, and Phlow Corp. (Phlow), a public benefit essential medicines solutions provider, today announced an alliance to reliably supply high-quality essential medicines utilizing advanced manufacturing processes based in the USA.
October 7, 2021
Michigan State University’s Axia Institute Announces the Launch of Axia Lab™ as its RFID Tag Validation Program

The Axia Institute of Michigan State University announced the creation of Axia Lab™, a premier research and consulting service leading the way in radio frequency identification (RFID) tagged item assessments, testing, compliance, and technical implementations. Axia Lab provides a neutral environment to facilitate impartial testing of the performance of RFID-tagged items according to GS1 Standards.
September 30, 2021
Fresenius Kabi and Health Care Logistics, Inc. Collaborate on RFID Compatibility

Fresenius Kabi and Health Care Logistics®, Inc. (HCL) today announced a collaboration designed to make drug replenishment in hospitals more efficient and improve patient safety throughout the medication-use process. The new collaboration allows customers to utilize Fresenius Kabi’s +RFID™ smart-labeled medications with HCL’s Stat Stock® inventory control solution.
September 7, 2021
Fresenius Kabi provides update on clinical trials for biosimilar candidate Tocilizumab.

Fresenius Kabi, a global healthcare company that specializes in lifesaving medicines and technologies, announced today that its tocilizumab biosimilar candidate MSB11456 successfully met its primary and secondary endpoints in two consecutively conducted clinical trials. The two Phase 1 studies used respectively subcutaneous and intravenous formulations to capture the two different routes of administration to evaluate the tocilizumab biosimilar candidate’s bioequivalence, safety and immunogenicity, in comparison to its reference candidates.
September 5, 2021
Fresenius Kabi and AABB Celebrate 16th Annual Blood Collectors Week

Fresenius Kabi and AABB announced that today begins the celebration of the 16th annual Blood Collectors Week (Sunday, September 5 through Saturday, September 11, 2021).
July 6, 2021
Fresenius Kabi Introduces New Simplist® Fentanyl Citrate Injection, USP 50 mcg per 1 mL in Ready-to-Administer Prefilled Syringe

Fresenius Kabi announced today the U.S. introduction of Fentanyl Citrate Injection, USP 50 mcg per 1 mL in its proprietary Simplist® ready-to-administer prefilled syringe, the only 1 mL presentation available in the U.S. today.
June 21, 2021
Fresenius Kabi Receives Premier Supplier Legacy Award

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has received a 2021 Supplier Legacy Award from Premier Inc. (www.premierinc.com), a leading health care improvement company.
June 15, 2021
Lindsey Thomas appointed to ASHP Foundation Board of Directors

The ASHP Foundation today announced the appointment of Lindsey Thomas and Ellen Wetterling to the ASHP Foundation Board of Directors as directors at large.
May 21, 2021
Temsirolimus Injection Now Available from Fresenius Kabi

Fresenius Kabi announced today the immediate availability of Temsirolimus Injection in the United States. Fresenius Kabi’s Temsirolimus Injection is supplied as a kit including one vial of 25 mg/mL Temsirolimus solution and one vial of diluent.
April 21, 2021
Fresenius Kabi Introduces Low Concentration Heparin Sodium in Sodium Chloride Injection in Ready-to-Use Freeflex® Bags

Fresenius Kabi announced today it has introduced in the United States two new presentations of Heparin Sodium in convenient, ready-to-administer Freeflex® IV bags.
April 1, 2021
Fresenius Kabi Signs Exclusive U.S. Distribution Agreement with Corvida Medical for the HALO® Closed System Drug-Transfer Device

Fresenius Kabi, a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, today announced it has signed an exclusive distribution agreement for the U.S. with Corvida Medical.
March 15, 2021
Fresenius Kabi Introduces First-Ever Generic for Foscavir® (Foscarnet Sodium) Injection

Fresenius Kabi announced today the immediate availability in the United States of Foscarnet Sodium Injection. Fresenius Kabi Foscarnet Sodium Injection is available in 6000 mg / 250 mL bottle.
January 8, 2021
Fresenius Kabi Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP Due to the Presence of Particulate Matter

Fresenius Kabi USA is voluntarily recalling a single lot of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter.
December 10, 2020
Fresenius Kabi Announces Availability of Acetaminophen Injection for Intravenous use in Ready-to-Use freeflex® Bags

Fresenius Kabi announced today the immediate availability in the United States of acetaminophen injection in freeflex® bags.
December 9, 2020
Fresenius Kabi and Kit Check Collaborate on RFID Compatibility

resenius Kabi and Kit Check today announced the companies have entered into an agreement under which Fresenius Kabi +RFID™ medications will be read by the Kit Check inventory management solution. The collaboration signals both companies’ commitment to medication safety and quality patient care across the health care continuum.
December 1, 2020
Fresenius Kabi Launches Icatibant Injection to Treat Acute Attacks of Hereditary Angioedema in Adults

Fresenius Kabi announced today it has introduced icatibant injection in the United States with immediate availability. Icatibant injection is an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema (HAE) in adults.
November 19, 2020
Fresenius Kabi Issues Voluntary Nationwide Recall of a Single Lot of Dexmedetomidine Hydrochloride Injection Due to Cross-Contamination of Lidocaine

Fresenius Kabi USA is voluntarily recalling a single lot of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4 mcg /mL), 50 mL fill in a 50 mL vial. Fresenius Kabi initiated this recall due to a trace amount of lidocaine present in the lot. This recall is being performed to the user level.
November 16, 2020
Fresenius Kabi Announces Inductees to Blood Donation Hall of Fame

Fresenius Kabi announced today it has inducted 13 people and organizations as the 2020 class of the Fresenius Kabi Blood Donation Hall of Fame, a nationwide program that recognizes and shares the unique stories of individuals from across the country who are passionate about and committed to blood donation, by donating themselves, and encouraging others to do so as well.
October 8, 2020
Diprivan® (Propofol) Injectable Emulsion, USP is First Product Available in Fresenius Kabi +RFID™ Portfolio of Smart-Labeled Medications

Fresenius Kabi announced today it has introduced the first in a growing line of medications that come with smart labels embedded with radio-frequency identification technology. The first +RFID™ smart-labeled product, Diprivan® (Propofol) 200 mg per 20 mL (10 mg per mL) Injectable Emulsion, USP, is now available in the United States.
September 6, 2020
Fresenius Kabi and AABB Celebrate 15th Annual Blood Collectors Week

Fresenius Kabi and AABB are celebrating the 15th annual Blood Collectors Week September 6-12, 2020.
August 18, 2020
Fresenius Kabi Introduces RFID Smart Labels for a Range of Essential Medications

Fresenius Kabi announced today it is introducing smart labels for a range of essential medications used in hospitals. The new labels, which feature embedded radio-frequency identification (RFID) technology, will be introduced this year for medications commonly used in the operating room, with the first product launching in September.
July 22, 2020
Fresenius Kabi Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine Hydrochloride Injection Due to Cross-Contamination of Lidocaine

Fresenius Kabi USA is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4 mcg / mL), 50 mL fill in a 50 mL vial. Fresenius Kabi initiated this recall due to the possibility of a trace amount of lidocaine present in these two lots and our investigation indicates that this issue is limited to these two product lots. This recall is being performed to the user level.
June 23, 2020
Fresenius Kabi Expands MicroVault® Packaging to include Simplist® Morphine Sulfate Injection, USP Ready-to-Administer Prefilled Syringes

Fresenius Kabi announced today the availability in the United States of Simplist® Morphine Sulfate Injection, USP 2 mg per 1 mL and 4 mg per 1 mL ready-to-administer prefilled syringes in MicroVault packaging.
June 15, 2020
Sedative that Received FDA Emergency Use Authorization Now Available from Fresenius Kabi for use in Mechanically Ventilated COVID-19 patients

Fresenius Kabi announced today that following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA), Fresenius Kabi Propoven 2% (propofol 20 mg/mL) Emulsion 100 mL is now available in the U.S. The drug provides sedation via continuous infusion in patients greater than 16 years old who require mechanical ventilation in an intensive care unit (ICU).
May 27, 2020
FDA Accepts for Review Fresenius Kabi’s BLA Submission for Pegfilgrastim Biosimilar

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today the U.S. Food and Drug Administration has accepted for review the company’s Biologics License Application (BLA) for MSB11455, the company’s pegfilgrastim biosimilar candidate for Neulasta®.
May 12, 2020
Fresenius Kabi Adds Micafungin for Injection to Expanding Anti-Infective Portfolio

Fresenius Kabi announced today the immediate availability in the United States of Micafungin for Injection.
May 7, 2020
Fresenius Kabi Announces Availability of Potassium Phosphates Injection, USP in Three Presentations

Fresenius Kabi announced today the immediate availability in the United States of Potassium Phosphates Injection, USP in the following presentations: 15 mM per 5 mL, 45 mM per 15 mL and 150 mM per 50 mL.
April 20, 2020
Fresenius Kabi Issues Voluntary Nationwide Recall of 13 Lots of Ketorolac Tromethamine Injection, USP Due to the Presence of Particulate Matter in Reserve Samples

Fresenius Kabi USA, LLC is voluntarily recalling 13 lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial and Ketorolac Tromethamine Injection, USP, 60 mg/2 mL (30 mg/mL), 2 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter composed of the following elements: carbon, silicon, oxygen and polyamides. Particulate matter was found in eight reserve sample vials.
April 7, 2020
TO HONOR AMERICA’S NURSES ON THE FRONT LINES OF THE COVID-19 RESPONSE, KINO LORBER LAUNCHES FREE STREAMING OF ACCLAIMED DOCUMENTARY ‘THE AMERICAN NURSE’

At no time in recent history has the vital role of nurses in America been so clear. To honor nurses on the front lines of the COVID-19 crisis, Kino Lorber is offering a free streaming re-release of the acclaimed documentary, THE AMERICAN NURSE (www.americannurseproject.com)
February 5, 2020
Fresenius Kabi Introduces Glucagon Emergency Medicine Kit to Treat Life-Threatening Episodes of Low Blood Sugar

Fresenius Kabi announced today the availability in the United States of its Glucagon Emergency Kit, an FDA-approved and cost-effective alternative to treat severe hypoglycemic episodes in people with diabetes.
January 29, 2020
CMS Assigns HCPCS Level II Code for Omegaven® (fish oil triglycerides) from Fresenius Kabi

he Centers for Medicare and Medicaid Services (CMS) has assigned an HCPCS Level II code to Omegaven®, the newest parenteral nutrition product introduced in the United States by Fresenius Kabi.
January 21, 2020
Three Industry Leaders Form New Venture to Create Scalable Manufacturing Platforms for Cell and Gene Therapies

Bio-Techne, Fresenius Kabi, and Wilson Wolf have formed a new joint venture company to provide dedicated support to researchers and biopharmaceutical companies in the field of cell and gene therapy.
December 19, 2019
Fresenius Kabi Announces Availability of Dicyclomine Hydrochloride Injection, USP 20 mg Vial

Fresenius Kabi announced today the immediate availability in the United States of Dicyclomine Hydrochloride Injection, USP in 20 mg per 2 mL single-dose vial.
December 11, 2019
Fresenius Kabi Expands Anti-Infective Portfolio with Launch of Ertapenem for Injection in 1 Gram Vial Presentation

Fresenius Kabi announced today the availability in the United States of Ertapenem for Injection in a 1 gram vial presentation. The new product is the generic equivalent to Invanz®.
November 20, 2019
American Society of Anesthesiologists Announces Continued Partnership with Fresenius Kabi as Industry Supporter

The American Society of Anesthesiologists (ASA) announced today that Fresenius Kabi USA will continue its partnership with ASA as an ASA Industry Supporter.
November 13, 2019
Fresenius Kabi Announces Availability of Fosaprepitant for Injection 150 mg per vial

Fresenius Kabi announced today the immediate availability in the United States of Fosaprepitant for Injection 150 mg per vial, the newest addition to the company’s generic oncology portfolio.
November 8, 2019
Fresenius Kabi Introduces Heparin Sodium Injection, USP Simplist® Prefilled Syringe in 5,000 USP units per 0.5 mL presentation

Fresenius Kabi announced today the availability in the United States of preservative-free Heparin Sodium Injection, USP in 5,000 USP units per 0.5 mL in Simplist® ready-to-administer prefilled syringes.
October 30, 2019
Fresenius Kabi Announces 2019 Inductees to Blood Donation Hall of Fame

Fresenius Kabi announced today it has inducted 15 people into the 2019 Fresenius Kabi Blood Donation Hall of Fame.
October 7, 2019
Fresenius Kabi Announces Availability of Fulvestrant Injection 250mg per 5mL prefilled syringe

Fresenius Kabi announced today the immediate availability in the United States of Fulvestrant Injection 250mg per 5mL prefilled syringe, an expansion of the company’s broad portfolio of injectable oncology medicines.
September 3, 2019
Fresenius Kabi and AABB Celebrate 14th Annual Blood Collectors Week

Fresenius Kabi and AABB are celebrating the 14th annual Blood Collectors Week September 1-7, 2019.
August 30, 2019
Fresenius Kabi Introduces Phenylephrine Hydrochloride Injection, USP

Fresenius Kabi announced today the immediate availability in the United States of Phenylephrine Hydrochloride Injection, USP.
July 16, 2019
Fresenius Kabi chooses Kenosha County for regional distribution center

Fresenius Kabi, a global health care company, is establishing a regional distribution center in Pleasant Prairie. The multimillion-dollar investment is expected to create 95 jobs over the next four years.
July 8, 2019
Fresenius Kabi Introduces Levothyroxine Sodium Injection Solution

Fresenius Kabi announced today the immediate availability in the United States of Levothyroxine Sodium Injection Solution in 100 mcg per 5 mL, 200 mcg per 5 mL and 500 mcg per 5 mL single-dose vials.
June 20, 2019
Fresenius Kabi Introduces Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection

Fresenius Kabi announced today the immediate availability in the United States of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a medication for sedation of non-intubated patients prior to and/or during surgical and other procedures.
June 10, 2019
Fresenius Kabi Introduces Neostigmine Methylsulfate Injection, USP Simplist® Prefilled Syringe in 3 mg per 3 mL Presentation

Fresenius Kabi announced today the immediate availability in the United States of Neostigmine Methylsulfate Injection, USP in 3 mg per 3 mL Simplist® ready-to-administer prefilled syringes
May 15, 2019
Premier’s ProvideGx™ Subsidiary and Fresenius Kabi Collaborate to Address Drug Shortages for Five Critical Medications

ProvideGx, LLC, a consolidated subsidiary of Premier Inc. (NASDAQ: PINC) and a healthcare improvement company developing a more stable and reliable supply chain for generic drugs in short supply, is collaborating with Fresenius Kabi to help mitigate national shortages of injectable thiamine, lidocaine, diphenhydramine, hydromorphone and morphine sulfate.
April 29, 2019
Fresenius Kabi Introduces Glycopyrrolate Injection, USP Simplist® Prefilled Syringes in 0.2 mg per 1 mL and 0.4 mg per 2 mL Presentations

Fresenius Kabi announced today the immediate availability in the United States of Glycopyrrolate Injection, USP in 0.2 mg per 1 mL and 0.4 mg per 2 mL single dose in Simplist® ready-to-administer prefilled syringes.
April 8, 2019
Fresenius Kabi Introduces Adenosine Injection, USP Simplist® Prefilled Syringes in 6 mg per 2 mL and 12 mg per 4 mL Presentations

Fresenius Kabi announced today the immediate availability in the United States of Adenosine Injection, USP in 6 mg per 2 mL and 12 mg per 4 mL single dose in Simplist® ready-to-administer prefilled syringes.
February 15, 2019
Fresenius Kabi Receives 510(k) Clearance for the Fenwal Amicus® Red Blood Cell Exchange Protocol

Fresenius Kabi today announced it has received 510(k) clearance from the U.S. Food and Drug Administration for the Fenwal Amicus® Red Blood Cell Exchange (RBCx) system.
February 12, 2019
Methocarbamol Injection, USP Now Available from Fresenius Kabi

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today the immediate availability in the United States of Methocarbamol Injection, USP in a 100 mg per mL 10 mL vial presentation.
January 29, 2019
Fresenius Kabi Introduces Leucovorin Calcium Injection, USP

Fresenius Kabi announced today the immediate availability in the United States of Leucovorin Calcium Injection, USP, a medication indicated to counteract the toxicity and diminish the effects of impaired methotrexate elimination.
December 10, 2018
Fresenius Kabi Announces U.S. Availability of Omegaven® (fish oil triglycerides) Injectable Emulsion

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today that Omegaven® (fish oil triglycerides) injectable emulsion is now commercially available in the United States. This novel lipid had previously been available only for compassionate use in the U.S.
December 3, 2018
Fresenius Kabi Receives FDA Drug Shortage Assistance Award

Fresenius Kabi announced today it has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA).
November 20, 2018
Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level.
October 26, 2018
Fresenius Kabi Introduces Leukemia Drug Arsenic Trioxide Injection in 10 mg per 10 mL vial

Fresenius Kabi announced today the immediate availability in the United States of Arsenic Trioxide Injection in a 10 mg per 10 mL vial presentation.
October 22, 2018
Fresenius Kabi Introduces Simplist® Palonosetron Hydrochloride Injection Prefilled Syringe

Fresenius Kabi announced today the immediate availability in the United States of the Simplist® Palonosetron Hydrochloride Injection. The Simplist® Palonosetron Hydrochloride Injection is available in a 0.25 mg per 5 mL single dose ready-to-administer prefilled syringe.
August 1, 2018
Fresenius Kabi Introduces Four Presentations of Heparin Sodium in freeflex® Containers

Fresenius Kabi announced today it has introduced four new presentations of Heparin Sodium in the company’s proprietary ready-to-administer freeflex® containers.
July 19, 2018
Atropine Sulfate Injection, USP Now Available From Fresenius Kabi

Fresenius Kabi announced today the immediate availability in the United States of Atropine Sulfate Injection, USP in an 8 mg per 20 mL presentation.
July 18, 2018
Glycopyrrolate Injection, USP Now Available from Fresenius Kabi

Fresenius Kabi announced today the immediate availability in the United States of Glycopyrrolate Injection, USP in 0.2 mg per mL, 0.4 mg per 2 mL, 1 mg per 5 mL and 4 mg per 20 mL presentations.
July 18, 2018
10th Annual Access and Savings Report Shows Savings from Generic and Biosimilar Medicines at Risk

Today, the Association for Accessible Medicines (AAM) released its “Generic Access and Savings Report in the United States 2018,” which finds that 93 percent of generic prescriptions are filled at $20 or less, and that the average co-pay for a generic drug is just $6.06.
July 10, 2018
Fresenius Kabi Introduces Adenosine Injection, USP in 60 mg per 20 mL and 90 mg per 30 mL Presentations

Fresenius Kabi announced today the immediate availability in the United States of Adenosine Injection, USP in 60 mg per 20 mL and 90 mg per 30 mL presentations.
April 16, 2018
Fresenius Kabi Melphalan Hydrochloride for Injection Now Available

Fresenius Kabi announced today the immediate availability in the United States of Melphalan Hydrochloride for Injection. Fresenius Kabi Melphalan Hydrochloride for Injection is available as a two-vial kit containing one single dose vial of Melphalan Hydrochloride equivalent to 50 mg Melphalan and one vial of sterile diluent.
April 12, 2018
Fresenius Kabi Announces New Approval and Immediate Availability of Daptomycin for Injection

Fresenius Kabi announced today it has received FDA approval for Daptomycin for Injection and the product is available immediately for customers in the United States. Daptomycin for Injection is an antibiotic and a generic alternative to CUBICIN®.
April 11, 2018
Fresenius Kabi Introduces Palonosetron Hydrochloride Injection

Fresenius Kabi announced today the immediate availability in the United States of Palonosetron Hydrochloride Injection.
January 26, 2018
Remifentanil Hydrochloride for Injection CII Now Available from Fresenius Kabi

Fresenius Kabi announced today the immediate availability in the United States of Remifentanil Hydrochloride for Injection.
January 22, 2018
Fresenius Kabi and ASPEN Launch Lipid Injectable Emulsion Best Practice Video Series

The American Society for Parenteral and Enteral Nutrition (ASPEN) and Fresenius Kabi announced today a new educational video series highlighting best practices for dosing, preparing and administering intravenous lipid emulsions (ILE).
January 12, 2018
Fresenius Kabi Introduces Bortezomib for Injection

Fresenius Kabi announced today the availability in the United States of Bortezomib for Injection. Fresenius Kabi Bortezomib for Injection is available as a single dose vial containing 3.5 mg of lyophilized powder.

Upcoming Events

10 - 14 October 2025 San Antonio, TX

Anesthesiology 2025

Henry B. Gonzalez Convention Center San Antonio, TX

Go to ASAHQ website

14 - 15 October 2025 Alexandria, VA

PPF: Plasma Protein Forum 2025

The Westin Alexandria Old Town

Alexandria, VA

Go to the PPF website

24 - 29 October 2025 Chicago, IL

ACR: American College of Rheumatology

McCormick Place

Chicago, IL

Go to the ACR website

25 - 28 October 2025 San Diego, CA Live & Virtual

AABB: Association for the Advancement of Blood & Biotherapies 2025

San Diego Convention Center

San Diego, CA

Go to AABB website

5 - 8 November 2025 Chicago, IL

NASPGHAN: North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Postgraduate Course and Annual Meeting 2025

Sheraton Grand Chicago

Chicago, IL

Go to the NASPGHAN website

10 - 12 November 2025 San Diego, CA

BMWS: Biomanufacturing World Summit 2025

The Hilton San Diego Bayfront

San Diego, CA

Go to BMWS website

30 November - 5 December 2025 Chicago, IL Live & Virtual

RSNA 2025: Radiological Society of North America Scientific Assembly and Annual Meeting

McCormick Place Convention center Chicago, IL

Go to RSNA website

7 - 11 December 2025 Las Vegas, NV

ASHP: American Society of Health-System Pharmacists Midyear 2025 Clinical Meeting & Exhibition

Mandalay Bay

Las Vegas, NV

Go to ASHP website

8 - 10 December 2025 Lake Buena Vista, FL

AIBD: Advances in Inflammatory Bowel Disease

Swan & Dolphin

Lake Buena Vista, FL

Go to the AIBD website

9 - 12 March 2026 Las Vegas, NV

HIMSS 2026 Global Health Conference and Exhibition

The Venetian Convention & Expo Center, Caesars Forum, and Wynn

Las Vegas, NV

Go to HIMSS website

22 - 24 March 2026 Chicago, IL

SCCM: Society of Critical Care Medicine 2026

McCormick Place Convention Center

Chicago, IL

Go to the SCCM website

11 - 14 April 2026 Louisville, KY

INS: Infusion Nurses Society Annual Meeting 2026

The Galt Hotel Louisville, KY

Go to INS website

11 - 14 April 2026 New Orleans, LA

AORN: Association of periOperative Registered Nurses Global Surgical Conference & Expo 2026

Ernest N. Morial Convention Center

New Orleans, LA

Go to AORN website

18 - 21 April 2026 Denver, CO

NHIA: National Home Infusion Association Annual Conference 2026

Gaylord Rockies Resort and Convention Center

Denver, CO

Go to NHIA website

23 - 27 April 2026 Boston, MA

PAS: Pediatric Academic Society 2026

Thomas Michael Menino Convention & Exhibition Center

Boston, MA

Go to PAS website

6 - 9 May 2026 Dublin, Leinster

ISCT: International Society for Cell Therapies 2026

The Convention Centre Dublin

Dublin, Leinster

Go to ISCT website

13 - 17 May 2026 San Antonio, TX

ONS: Oncology Nursing Society Congress 2026

The Galt Hotel

Louisville, KY

Go to ONS website

19 - 20 May 2026 San Diego, CA Live & Virtual

AACN NTI - National Teaching Institute & Critical Care Exposition 2026

San Diego Convention Center

San Diego, CA

Go to AACN NTI website

1 - 30 September 2026 Date TBD | Boston, MA

CAR TCR Summit 2026

Venue TBD

Boston, MA

Go to Car-TCR Summit website

Newsroom

CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Conexxence® and Bomyntra® (denosumab-bnht)

Fresenius Kabi Receives Two Major Awards for Supply and Service Excellence from Vizient®

Fresenius Kabi and AABB Announce 20th Anniversary of Blood Collectors Week, September 7–14, 2025, Honoring Lifesaving Blood Collection Professionals

Fresenius leads new EASYGEN consortium aimed at decentralizing CAR-T cell therapy and improving hospital workflows

Fresenius Kabi Receives 2025 Premier Supplier Legacy Award

Fresenius Expands Biosimilars Portfolio With The Launch of Denosumab Biosimilars in the U.S.

Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg per 30 mL Multi-Dose Vials

FDA Grants Interchangeable Designation to Fresenius Kabi’s biosimilar Otulfi® (ustekinumab-aauz)

CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Otulfi® (ustekinumab-aauz)

Fresenius Receives FDA Approval for Their Denosumab Biosimilars and Secures Global Settlement Agreement

Fresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)

Angels for Change Launches Project GOLD

Fresenius Kabi Introduces Calcitonin Salmon Injection, USP Synthetic

Angels for Change Announce 2024 Change Maker of the Year Award.

Fresenius Kabi Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency with the Aurora Xi Plasmapheresis System

Fresenius Kabi Launches Epinephrine Injection, USP Expanding U.S. Pharma Portfolio

Ori Biotech and Fresenius Kabi Collaborate to Advance Modular, Scalable Manufacturing of Cell and Gene Therapies

Fresenius Kabi Submits 510(k) Notification for the Aurora Xi Plasmapheresis System Software Version 2.0 with New Nomogram

Fresenius Kabi Receives 2024 Novaplus Program Excellence Award from Vizient

CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code and Pass-Through Payment Status for Tyenne® (tocilizumab-aazg)

Fresenius Kabi Inducts 12 into National Blood Donation Hall of Fame

Cellular Origins, Fresenius Kabi Sign Development Agreement for Scalable Automation of Cell and Gene Therapy Manufacturing

Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi(TM)* (ustekinumab-aauz)

Fresenius Kabi and AABB Announce Start of 19th Annual Blood Collectors Week

Fresenius Kabi Expands Women’s Health Portfolio with New Generic Option for Reproductive Health

Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. for Supply Chain Innovation

Arunesh Verma Joins Fresenius Kabi USA as President

Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States

Angels for Change 2024 Drug Shortage Guardian Awarded to Fresenius Kabi USA

Fresenius Accelerates Momentum in its (Bio) Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.

Fresenius Kabi’s Biosimilar Tyenne® (tocilizumab-aazg) becomes the first IV and Subcutaneous tocilizumab biosimilar approved by the FDA

Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP

Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections

Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix® Infusion System

Fresenius Kabi Celebrates 25th Anniversary of National Blood Donation Hall of Fame by Honoring 2023 Heroes

Fresenius Kabi Introduces Smart Labels for Diprivan® with Embedded Fully Interoperable +RFID Technology

Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient

Fresenius Kabi Selected for Second Consecutive Year to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange

Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi

Fresenius Kabi and AABB Announce Start of 18th Annual Blood Collectors Week September 3-9, 2023

Fresenius Kabi and Lupagen Enter into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside

Fresenius Kabi Launches Plerixafor Injection

Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection

Supporting the Drug Supply Following the Recent Tornado in North Carolina

Fresenius Kabi Introduces New Presentation for Fentanyl Citrate Injection, USP in Simplist® Ready-to-Administer Prefilled Syringes

Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment

IDACIO® (adalimumab-aacf) Now Available in the United States

Metrodora Institute, a Leader in Treating Complex Conditions, Chooses the Ivenix Infusion System from Fresenius Kabi

Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection

Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio

Supporting Patient Safety: Fresenius Kabi Expands Ready-to-Administer Portfolio with Diazepam Injection, USP in Simplist® Prefilled Syringe

Fresenius Kabi Launches RFID-Enabled Rocuronium Bromide Injection, its First Product Compatible with Bluesight's KitCheck System

Fresenius Kabi Awarded Breakthrough Technology Agreement with Premier, Inc. for the Ivenix Infusion System

CMS grants Fresenius Kabi permanent, product-specific Q-Code for Stimufend® (pegfilgrastim-fpgk)

Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix Infusion System

Stimufend® (pegfilgrastim-fpgk) Now Available in the United States

Fresenius Kabi’s Ivenix Infusion System Goes Live at San Luis Valley Health

Fresenius Kabi Targets Treatment of Certain Seizures with Launch of Generic Lacosamide Injection, USP

Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio® (adalimumab-aacf)

Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Fresenius Kabi Introduces KabiCare Nutrition Resources for U.S. Parenteral Nutrition Products

Fresenius Kabi Announces 2022 Inductees to Blood Donation Hall of Fame

Fort HealthCare Goes Live with Smart Pump Interoperability with the Ivenix Infusion System from Fresenius Kabi

Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient

Fresenius Kabi Expands Contrast Agent Portfolio with Launch of Gadoterate Meglumine Injection, USP

Fresenius Kabi Selected to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange

Stimufend® (pegfilgrastim-fpgk) a Fresenius Kabi biosimilar receives FDA approval

Fresenius Kabi and AABB Celebrate 17th Annual Blood Collectors Week from September 4-10, 2022

Fresenius Kabi, a Leader in Injectable Medicines, Introduces Data Matrix Barcodes on all Drugs as part of Companywide Commitment to Medication Safety

Fresenius Kabi’s Biologic License Application for Biosimilar Candidate Tocilizumab Accepted for Review in the U.S.

Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa

Fresenius Kabi Expands Ready-to-Administer Portfolio with Glycopyrrolate Injection, USP Simplist® Prefilled Syringe

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Romidepsin for Injection Available from Fresenius Kabi

Fresenius Kabi Expands RFID Compatibility to Improve Hospital Inventory Management

Fresenius Kabi Introduces PEMEtrexed for Injection, USP in the U.S.

Dr. Brandee Pappalardo Joins Fresenius Kabi as Chief Medical Officer for North America

Fresenius Kabi Completes Acquisition of Ivenix

Fresenius Kabi Introduces New Generic for the Treatment of Multiple Myeloma